

Table S1. Characteristics of study subjects

Donor exposure(s)	Natural infection				mRNA vaccine		Natural infection plus mRNA vaccine	
	D614G	B.1.429	B.1.1.519	E484K	BNT162b2 vaccine	mRNA-1273 vaccine	D614G + BNT162b2	B.1.429 + BNT162b2
Count	n = 10	n = 15	n = 6	n = 2	n = 5	n = 6	n = 8	n = 17
Mean age (SD)	48.8 (12.6)	42.0 (11.2)	37.5 (7.3)	32.5 (2.1)	32.4 (11.3)	29.8 (6.9)	43.9 (12.3)	40.5 (9.2)
Sex								
Female (%)	5 (50%)	10 (66.7%)	4 (66.7%)	0 (0%)	4 (66.6%)	2 (40%)	1 (12.5%)	9 (52.9%)
Male (%)	5 (50%)	5 (33.3%)	2 (33.3%)	2 (100%)	2 (33.3%)	3 (60%)	7 (87.5%)	8 (47.1%)
Symptoms								
Yes (%)	8 (80.0%)	9 (60.0%)	4 (66.7%)	2 (100%)			5 (62.5%)	9 (52.9%)
No (%)	2 (20.0%)	5 (33.3%)	2 (33.3%)	0 (0.0%)			2 (25.0%)	7 (41.2%)
Unknown (%)	0 (0.0%)	1 (6.7%)	0 (0.0%)	0 (0.0%)			1 (12.5%)	1 (5.9%)
Days post COVID19+ (SD)	56 (19.1)	38.7 (6.1)	38.5 (8.9)	36 (11.3)			116 (11.2)	107.1 (13.2)
Days post vaccine (SD)					16 (2.8)	35 (13.3)	19.5 (6.9)	28.4 (13.1)